Andrew Cooper
Stock Analyst at Raymond James
(2.38)
# 2,590
Out of 5,030 analysts
148
Total ratings
43.18%
Success rate
-0.19%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTR Avantor | Maintains: Outperform | $14 → $16 | $14.78 | +8.25% | 16 | Oct 16, 2025 | |
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $50.26 | +55.19% | 10 | Aug 11, 2025 | |
| AZTA Azenta | Upgrades: Outperform | $35 | $30.97 | +13.01% | 2 | Aug 6, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $65.46 | -6.81% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $93.42 | +23.10% | 9 | Jul 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $150 → $143 | $104.83 | +36.41% | 3 | Jul 25, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $538.92 | -0.73% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $7.80 | +28.21% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $22.68 | +10.23% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $69.85 | +1.65% | 12 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $195.32 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $209.06 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $61.23 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.41 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $181.69 | -53.22% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $28.13 | +170.17% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $3.96 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.05 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $35.83 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $3.02 | - | 5 | Sep 22, 2021 |
Avantor
Oct 16, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $14.78
Upside: +8.25%
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $50.26
Upside: +55.19%
Azenta
Aug 6, 2025
Upgrades: Outperform
Price Target: $35
Current: $30.97
Upside: +13.01%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $65.46
Upside: -6.81%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $93.42
Upside: +23.10%
Integer Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $150 → $143
Current: $104.83
Upside: +36.41%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $538.92
Upside: -0.73%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $7.80
Upside: +28.21%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $22.68
Upside: +10.23%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $69.85
Upside: +1.65%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $195.32
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $209.06
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $61.23
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $14.41
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $181.69
Upside: -53.22%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $28.13
Upside: +170.17%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $3.96
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.05
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $35.83
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $3.02
Upside: -